Cargando…
Tofacitinib May Inhibit Myofibroblast Differentiation from Rheumatoid-Fibroblast-like Synoviocytes Induced by TGF-β and IL-6
During rheumatoid arthritis (RA), the pathogenic role of resident cells within the synovial membrane is suggested, especially for a population frequently referred to as fibroblast-like synoviocytes (FLSs). In this study, we assess the markers of myofibroblast differentiation of RA-FLSs by ex vivo ob...
Autores principales: | Ruscitti, Piero, Liakouli, Vasiliki, Panzera, Noemi, Angelucci, Adriano, Berardicurti, Onorina, Di Nino, Elena, Navarini, Luca, Vomero, Marta, Ursini, Francesco, Mauro, Daniele, Dolo, Vincenza, Ciccia, Francesco, Giacomelli, Roberto, Cipriani, Paola |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9147406/ https://www.ncbi.nlm.nih.gov/pubmed/35631449 http://dx.doi.org/10.3390/ph15050622 |
Ejemplares similares
-
Blocking CD248 molecules in perivascular stromal cells of patients with systemic sclerosis strongly inhibits their differentiation toward myofibroblasts and proliferation: a new potential target for antifibrotic therapy
por: Di Benedetto, Paola, et al.
Publicado: (2018) -
Blocking Jak/STAT signalling using tofacitinib inhibits angiogenesis in experimental arthritis
por: Di Benedetto, Paola, et al.
Publicado: (2021) -
Managing Adult-onset Still's disease: The effectiveness of high-dosage of corticosteroids as first-line treatment in inducing the clinical remission. Results from an observational study
por: Ruscitti, Piero, et al.
Publicado: (2019) -
Poor clinical response in rheumatoid arthritis is the main risk factor for diabetes development in the short-term: A 1-year, single-centre, longitudinal study
por: Ruscitti, Piero, et al.
Publicado: (2017) -
Prevalence of type 2 diabetes and impaired fasting glucose in patients affected by rheumatoid arthritis: Results from a cross-sectional study
por: Ruscitti, Piero, et al.
Publicado: (2017)